BEIGF:OTCMKTS
BeOne Medicines
21,95 US$
0,00%
(0,00) 1D
9 qer, 12:49:46 m.d., GMT-4 · USD
search
Të gjitha simbolet
| Me simbole | Çmimi | Ndrysho | % ndryshim |
|---|
insights_autoPo gjenerohen statistikat kryesore për BEIGF...
Kapitalizimi i tregut
42,40 mld
Vëllimi mesatar
0,00
Vëllimi
0,00
Maksimumi 52-javor
24,92 US$
Minimumi 52-javor
21,95 US$
Beta
0,84
Aksionet në qarkullim
1,43 mld
Numri i punonjësve
12 mijë
Kapitalizimi i tregut
42,40 mld
Vëllimi mesatar
0,00
Vëllimi
0,00
Maksimumi 52-javor
24,92 US$
Minimumi 52-javor
21,95 US$
Beta
0,84
Aksionet në qarkullim
1,43 mld
Numri i punonjësve
12 mijë
Lajmet
Nga burimet në ueb dhe partnerët e lajmeve
Simply Wall Street
·
2 minuta më parë
After AbCellera Biologics' 125% Climb, The Story Has Changed
CoinDesk
·
2 orë më parë
Bitcoin rebounds above $83,000 as it decouples from tumbling Korean stocks and Nasdaq futures
Carroll County Mirror-Democrat
·
45 minuta më parë
Abishai Financial Asia Reports S&P 500 Tech-Led Advance
Yahoo Finance
·
47 minuta më parë
Stock Market: Will S&P 500 Open Up or Down Today?
Profili
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
Rreth BeOne Medicines
Drejtori ekzekutivJohn Vincent Oyler | John Vincent Oyler
Punonjësit12 mijë
Themeluar më28 tet 2010
Selia-
Sektori-
Uebsajtibeonemedicines.com